Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial | Zendy

Peter Schmid | Zendy; Jacinta Abraham | Zendy; Stephen Chan | Zendy; Duncan Wheatley | Zendy; Adrian Murray Brunt | Zendy; Gia Nemsadze | Zendy; Richard D. Baird | Zendy; Winnie Yeo | Zendy; Peter Hall | Zendy; Timothy Perren | Zendy; Robert C. Stein | Zendy; László Mangel | Zendy; JeanMarc Ferrero | Zendy; Melissa Phillips | Zendy; John Conibear | Zendy; Javier Cortés | Zendy; Andrew Foxley | Zendy; Elza C. de Bruin | Zendy; Robert McEwen | Zendy; Daniel Stetson | Zendy; Brian Dougherty | Zendy; ShahJalal Sarker | Zendy; Aaron Prendergast | Zendy; Max McLaughlin-Callan | Zendy; Matthew Burgess | Zendy; Cheryl Lawrence | Zendy; Hayley Cartwright | Zendy; Kelly Mousa | Zendy; Nicholas C. Turner | Zendy

Open Access

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Author(s) -

Peter Schmid,

Jacinta Abraham,

Stephen Chan,

Duncan Wheatley,

Adrian Murray Brunt,

Gia Nemsadze,

Richard D. Baird,

Winnie Yeo,

Peter Hall,

Timothy Perren,

Robert C. Stein,

László Mangel,

JeanMarc Ferrero,

Melissa Phillips,

John Conibear,

Javier Cortés,

Andrew Foxley,

Elza C. de Bruin,

Robert McEwen,

Daniel Stetson,

Brian Dougherty,

ShahJalal Sarker,

Aaron Prendergast,

Max McLaughlin-Callan,

Matthew Burgess,

Cheryl Lawrence,

Hayley Cartwright,

Kelly Mousa,

Nicholas C. Turner

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.00368

Subject(s) - medicine , paclitaxel , placebo , hazard ratio , metastatic breast cancer , breast cancer , pten , oncology , clinical endpoint , triple negative breast cancer , chemotherapy , cancer , gastroenterology , clinical trial , pi3k/akt/mtor pathway , pathology , confidence interval , apoptosis , biochemistry , chemistry , alternative medicine

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research